ClinConnect ClinConnect Logo
Search / Trial NCT00820820

IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis

Launched by INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FRANCE · Jan 9, 2009

Trial Information

Current as of July 22, 2025

Completed

Keywords

Atopic Dermatitis Immunosuppression Measles Vaccine T Lymphocytes Atopic Dermatitis In Adults

ClinConnect Summary

Atopic dermatitis (AD) is a chronic inflammatory disease of the skin. AD is very frequent, and involves T lymphocytes cells. Measles vaccination, as well as measles vaccine, induces a temporary immunosuppression; furthermore, an improvement of AD has been observed during measles infection.

This trial is aimed at demonstrating that measles vaccine is able to create an immunomodulation and to improve AD symptoms.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • adults patients of both sexes, with moderate to severe Atopic Dermatitis (SCORAD (Score for Atopic Dermatitis) ≥ 15).
  • Exclusion Criteria:
  • hypersensititvity or contra-indication to a Rouvax® component, Tubertest® component, to egg proteins, immunological deficiency, pregnancy, neomycin
  • allergy,
  • systemic immnosuppressive treatment in the previous 3 months,
  • topic immunosuppressive treatment during the week preceeding the inclusion (gluco-corticoid, or immunosuppressive agent),
  • fever or acute disease (the inclusion must be postpone in such cases).

About Institut National De La Santé Et De La Recherche Médicale, France

The Institut National de la Santé et de la Recherche Médicale (INSERM) is France's key public research organization dedicated to advancing knowledge in health and biomedical sciences. Established to foster innovation and improve public health outcomes, INSERM conducts a wide range of clinical trials and research initiatives aimed at translating scientific discoveries into effective medical treatments and interventions. With a focus on collaboration among researchers, healthcare professionals, and industry partners, INSERM plays a pivotal role in shaping health policies and enhancing the quality of care in France and beyond.

Locations

Pierre Bénite, Lyon, France

Patients applied

0 patients applied

Trial Officials

Branka Horvat, MD, PhD

Study Director

Institut National de la Santé Et de la Recherche Médicale, France

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials